Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or With Severe Hypertriglyceridemia

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or With Severe Hypertriglyceridemia

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olezarsen (Primary)
  • Indications Cardiovascular disorders; Hypertriglyceridaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ESSENCE
  • Sponsors Ionis Pharmaceuticals

Most Recent Events

  • 19 May 2025 Primary endpoint (Percent Change From Baseline to Week 25 in Fasting Triglycerides (TG) Compared to Placebo) has been met.
  • 19 May 2025 Results presented in the Ionis Media Release.
  • 30 Apr 2025 According to Ionis Pharmaceuticals media release, study design and baseline characteristics for CORE, CORE2 and ESSENCE studies were published in the American Heart Journal.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top